BRISBANE – ResApp Health Limited has received institutional review board approval for the SMARTCOUGH-C study at Baylor College of Medicine, Texas Children’s Hospital, Cleveland Clinic and Massachusetts General Hospital.
“Our ultimate goal is to demonstrate the clinical accuracy of ResAppDx and improve the health care for children everywhere,” sasid Tony Keating, managing director and CEO of ResApp, in a statement.
SMARTCOUGH-C is a prospective, multi-site, double-blind study that will evaluate the efficacy of the ResAppDx software application in the diagnosis of childhood pneumonia and other respiratory conditions from cough sounds.
The primary endpoints for the study will be the diagnosis of pneumonia, with secondary endpoints being diagnosis of other common childhood respiratory diseases, such as upper respiratory tract infection, croup, bronchiolitis and asthma.
The details of the study will be published in the U.S. National Institutes of Health clinical trials database.